Drug Trial Radar · NCT06292780
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Aug 7, 2024
Primary completion
Aug 20, 2028
Study completion Feb 20, 2035
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 phases (Phase 1 and Phase 2): * In Phase 1, linvoseltamab will be given to a small number of participants to study the side effects of the study drug and to determine the recommended doses of the study drug to be given to participants in Phase 2. * In Phase 2, linvoseltamab will be given to more participants to continue to assess the side effects of the study drug and to evaluate the ability of linvoseltamab to treat AL amyloidosis. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab have improvement in the abnormal proteins that cause organ problems and for how long * How many participants treated with linvoseltamab have improvement in the heart or kidney and for how long * What the right dosing regimen is for linvoseltamab * What side effects may happen from taking linvoseltamab * How much linvoseltamab is in the blood at different times * Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects)
Conditions
- Relapsed/Refractory Systemic Light Chain Amyloidosis
Interventions
LinvoseltamabDrug
anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity (DLTs)Time frame: Up to 28 Days
- Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)Time frame: Up to 3 years
Locations
24 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Colorado Blood Cancer Institute/SCRI
Denver, Colorado · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
National and Kapodistrian University of Athens
Athens, Greece · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul St. Mary's Hospital - The Catholic University of Korea
Seoul, South Korea · Recruiting
Universität de Barcelona- Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS)
Barcelona, Spain · Recruiting
University Hospital La Fe
Valencia, Spain · Recruiting
Hospital Universitari Son Espases
Palma, Balearic Islands, Spain · Recruiting
Clinica Universidad de Navarra - Pamplona
Pamplona, Navarre, Spain · Recruiting
Hospital de Cabuenes
Gijón, Principality of Asturias, Spain · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
Tri-Service General Hospital
Taipei, Taiwan · Recruiting
Taipei Municipal Wan Fang Hospital
Taipei, Taiwan · Recruiting
University College London Hospitals
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Withdrawn
Manchester Royal Infirmary
Manchester, Greater Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.